Skip to main content

Exelixis

Exelixis, Inc. is an American commercial-stage oncology biotechnology company discovering and commercializing small molecule targeted cancer therapies. The company focuses its operational activities on small molecule research, clinical trials, and oncology drug sales. Its flagship commercial formulation is cabozantinib, marketed under the trade names CABOMETYX and COMETRIQ for renal cell, hepatocellular, and thyroid carcinomas. Primary revenue drivers are commercial product sales of CABOMETYX in the United States alongside licensing royalties and development milestones from partners Ipsen and Takeda. Exelixis holds a market-leading position in targeted renal cell carcinoma therapeutics. The company is headquartered in Alameda, California, and its shares trade on the Nasdaq Global Select Market.

12 of the funds FundTelligence covers report a position in Exelixis.

Legal name
Exelixis Inc
Sector
Health Care
Country
United States
Funds holding it
12

Funds holding Exelixis

Showing the 8 largest of 12 funds holding it.

Loading...